Related Experiment Video

Updated: Apr 30, 2026

Flow Cytometry Analysis of Immune Cell Subsets within the Murine Spleen, Bone Marrow, Lymph Nodes and Synovial Tissue in an Osteoarthritis Model
12:23

Flow Cytometry Analysis of Immune Cell Subsets within the Murine Spleen, Bone Marrow, Lymph Nodes and Synovial Tissue in an Osteoarthritis Model

Published on: April 24, 2020

19.8K

Whole blood gene expression profiling predicts therapeutic response at six months in patients with polyarticular

Kaiyu Jiang1, Ashley D Sawle, M Barton Frank

  • 1Columbia University Medical Center, New York, New York.

Arthritis & Rheumatology (Hoboken, N.J.)
|May 1, 2014
PubMed

Insights

Gene expression in peripheral blood can predict treatment outcomes in children with polyarticular juvenile idiopathic arthritis (JIA). This finding suggests peripheral blood gene expression may be a valuable tool for a new prognostic test for JIA.

Area of Science:

  • Immunology
  • Genetics
  • Pediatrics

Background:

  • Juvenile idiopathic arthritis (JIA) is a complex autoimmune disease affecting children.
  • Identifying reliable prognostic markers for JIA is crucial for tailoring treatment strategies.
  • Current understanding of JIA pathogenesis involves intricate genetic and immune system interactions.

Purpose of the Study:

  • To investigate if peripheral whole blood gene expression profiles can predict therapeutic outcomes in children with newly diagnosed polyarticular JIA.
  • To explore the potential of gene expression analysis as a prognostic tool for JIA patients.

Main Methods:

  • Analysis of whole blood samples from the Trial of Early Aggressive Therapy (TREAT) in JIA patients using Illumina microarrays.
  • Validation of microarray findings using real-time quantitative polymerase chain reaction (RT-qPCR).
  • Application of pathway analysis and support vector machine (SVM) modeling to identify predictive gene expression signatures.

Main Results:

  • Gene expression profiles were similar between rheumatoid factor (RF)-positive and RF-negative JIA patients.
  • Pathway analysis indicated a wide array of biological pathways affected in JIA, aligning with existing mechanistic theories.
  • Predictive modeling demonstrated a strong correlation between baseline gene expression and 6-month prognosis, independent of treatment received.

Conclusions:

  • Peripheral blood gene expression is significantly associated with therapeutic outcomes in polyarticular JIA.
  • Gene expression analysis in peripheral blood holds promise as a basis for developing a novel prognostic test for JIA.
Abstract

More Related Videos

Author Spotlight: Assessing Intrathecal Gene Therapy Efficacy in Juvenile Rats04:38

Author Spotlight: Assessing Intrathecal Gene Therapy Efficacy in Juvenile Rats

Published on: March 29, 2024

1.9K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.2K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
10.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755